Aerovate Therapeutics, INC 8-K filings
Aerovate Therapeutics is implementing a significant workforce reduction, terminating 78% of its staff, after halting its Phase 2b/Phase 3 clinical trial of AV-101.
8-K: Aerovate Therapeutics' Phase 2b Trial for Pulmonary Hypertension Drug Fails to Meet Primary Endpoint
Aerovate Therapeutics' Phase 2b trial of AV-101 for pulmonary arterial hypertension did not meet its primary endpoint, leading to the halt of the Phase 3 trial.
Aerovate Therapeutics held its 2024 Annual Meeting of Stockholders on June 5, 2024, where they elected two Class III directors and ratified the appointment of KPMG LLP as their independent auditor.
Aerovate Therapeutics reported its first quarter 2024 financial results, highlighted by the upcoming topline data from its Phase 2b trial and a cash runway into 2026.
8-K: Aerovate Therapeutics Advances Inhaled PAH Treatment with AV-101, Phase 2b Data Expected June 2024
Aerovate Therapeutics is developing AV-101, an inhaled dry powder formulation of imatinib, for pulmonary arterial hypertension (PAH), aiming to improve patient outcomes by targeting the hyperproliferative cause of the disease.
Aerovate Therapeutics reported its full-year 2023 financial results, highlighted by the completion of enrollment in the Phase 2b portion of its IMPAHCT trial and the initiation of the Phase 3 portion, with topline data expected in June 2024.